11 results match your criteria: "Ontario Canada (L.E.S.); and RIKEN Center for Integrative Medical Science[Affiliation]"

Patent Foramen Ovale Closure in Older Patients With Stroke: Patient Selection for Trial Feasibility.

Neurology

May 2024

From the Predictive Analytics and Comparative Effectiveness (PACE) Center (A.Y.W., J.N., B.K., D.K., D.M.K.), Institute for Clinical Research and Health Policy Studies (ICRHPS), Tufts Medical Center, Boston, MA; Department of Clinical Neurology (P.M.R., L.L., S.M., L.E.S.), Oxford University, London, United Kingdom; Comprehensive Stroke Center and Department of Neurology (J.L.S.), David Geffen School of Medicine, University of California, Los Angeles; Comprehensive Stroke Center (S.E.K.), Department of Neurology, University of Pennsylvania Medical Center, Philadelphia; Division of Cardiology (J.C.), Department of Medicine, University of Colorado Denver, Aurora; Université Paris Cité (J.-L.M.), Institute of Psychiatry and Neuroscience of Paris (IPNP), INSERM U1266; GHU-Paris Psychiatrie et Neurosciences (J.-L.M.), Hôpital Sainte Anne; Département de Physiologie (G.D.), Hôpital Henri Mondor, Assistance Publique-Hôpitaux de Paris, Université Paris-Est Créteil (UPEC); Centre d'Investigations Cliniques (G.C.), Unité de Recherche Clinique, Hôpital Européen Georges-Pompidou, Assistance Publique-Hôpitaux de Paris, France; Department of Neurology (A.J.F.), Case Western Reserve University, Cleveland, OH; Division of Cardiovascular Medicine (H.C.H., B.L.), Perelman School of Medicine at the University of Pennsylvania, Philadelphia; Department of Population Health (P.J.), University of Oxford, United Kingdom; Department of Neurology (J.S.K.), Gangneung Asan Hospital, University of Ulsan College of Medicine; Department of Cardiology (P.H.L.), Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; Department of Neurology (H.P.M.), Bern University Hospital; Medical Faculty (B.M.), University of Bern, Switzerland; Cardiology Department (M.R.), Weill Cornell Medical Center, Cornell, NY; Division of Cardiology (R.W.S.), Department of Medicine, UTHealth/McGovern Medical School and The Memorial Hermann Heart and Vascular Institute, Houston, TX; Department of Cardiology (L.S.), Rigshospitalet, Copenhagen University Hospital, Denmark; Division of Cardiology (J.-K.S.), Asan Medical Center Heart Institute, University of Ulsan College of Medicine, Seoul, South Korea; BHF Cardiovascular Epidemiology Unit (E.D.A.), Department of Public Health and Primary Care, University of Cambridge; Victor Phillip Dahdaleh Heart and Lung Research Institute (E.D.A.), BHF Centre of Research Excellence, School of Clinical Medicine, Addenbrooke's Hospital; NIHR Blood and Transplant Research Unit in Donor Health and Behaviour (E.D.A.), all University of Cambridge; Health Data Research UK Cambridge (E.D.A.), Wellcome Genome Campus and University of Cambridge, Hinxton; University of Cambridge (E.D.A.), United Kingdom; Health Data Science Centre (E.D.A.), Human Technopole, Milan, Italy; Department of Medicine (M.D., S.H.), Columbia University, College of Physicians and Surgeons, New York, NY; Department of Neurology (M.S.V.E.), Vagelos College of Physicians and Surgeons, and Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY; Division of Neurology-Stroke Program (C.J.), Department of Medicine, University Health Network, Toronto Western Hospital, Ontario, Canada; Stroke Center (P.M.), Neurology Service, Lausanne University Hospital; Department of Neurology (M.-L.M., K.N.), University of Bern; Department of Neurology (M.-L.M.), Stadtspital Zürich; Department of Neurology and Stroke Centre (K.N.), Cantonal Hospital Aarau, Switzerland; Sapienza University of Rome (F.P.), Italy; Department of Neurology (J.S.), Hospital Universitari de Girona Dr Josep Trueta - IDIBGI, Spain; Department of Neurology and Stroke Center (C.W.), University Duisburg-Essen, Germany; Department of Public Health (D.K.), Erasmus University Medical Center, Rotterdam, the Netherlands; and Department of Neurology (D.E.T.), Tufts Medical Center/Tufts University School of Medicine, Boston, MA.

Background And Objectives: Whether patent foramen ovale (PFO) closure benefits older patients with PFO and cryptogenic stroke is unknown because randomized controlled trials (RCTs) have predominantly enrolled patients younger than 60 years of age. Our objective was to estimate anticipated effects of PFO closure in older patients to predict the numbers needed to plan an RCT.

Methods: Effectiveness estimates are derived from major observational studies (Risk of Paradoxical Embolism [RoPE] Study and Oxford Vascular Study, together referred to as the "RoPE-Ox" database) and all 6 major RCTs (Systematic, Collaborative, PFO Closure Evaluation [SCOPE] Consortium).

View Article and Find Full Text PDF

Inhibiting membrane rupture with NINJ1 antibodies limits tissue injury.

Nature

June 2023

Department of Physiological Chemistry, Genentech, South San Francisco, CA, USA.

Plasma membrane rupture (PMR) in dying cells undergoing pyroptosis or apoptosis requires the cell-surface protein NINJ1. PMR releases pro-inflammatory cytoplasmic molecules, collectively called damage-associated molecular patterns (DAMPs), that activate immune cells. Therefore, inhibiting NINJ1 and PMR may limit the inflammation that is associated with excessive cell death.

View Article and Find Full Text PDF
Article Synopsis
  • * It recommends testing Lp(a) levels in adults, especially those with a family history of high Lp(a) or premature ASCVD, and suggests aggressive management of cardiovascular risk factors in the absence of specific Lp(a)-lowering therapies.
  • * The statement underscores the need for further research into Lp(a)-lowering treatments while recognizing Lp(a) as a causal risk factor for cardiovascular conditions, reinforcing
View Article and Find Full Text PDF

Background: The economic burden of musculoskeletal diseases is substantial and growing. Economic evaluations compare costs and health benefits of interventions simultaneously to help inform value-based care; thus, it is crucial to ensure that studies are using appropriate methodology to provide valid evidence on the cost-effectiveness of interventions. This is particularly the case in orthopaedic sports medicine, where several interventions of varying costs are available to treat common hip and knee conditions.

View Article and Find Full Text PDF

A Novel Endovascular Therapy for CSF Hypotension Secondary to CSF-Venous Fistulas.

AJNR Am J Neuroradiol

May 2021

Department of Neurology (I.G., J.K.C.-G.), Mayo Clinic, Rochester, Minnesota.

We report a consecutive case series of patients who underwent transvenous embolization of the paraspinal vein, which was draining the CSF-venous fistula, for treatment of spontaneous intracranial hypotension. These are the first-ever reported cases of this treatment for CSF-venous fistulas. All patients underwent spinal venography following catheterization of the azygous vein and then selective catheterization of the paraspinal vein followed by embolization of the vein with Onyx.

View Article and Find Full Text PDF

Patients with renal impairment are at higher risk of thrombosis and bleeding than those with normal renal function. The optimal rivaroxaban dose for thromboprophylaxis in acutely ill medical patients with renal impairment is unknown. MARINER and MAGELLAN were multicenter, randomized clinical trials of rivaroxaban in acutely ill medical patients.

View Article and Find Full Text PDF

, a Novel Transcription Factor and a Coregulator of Nuclear Factor B p65: Single Nucleotide Polymorphism and Estrogen Dependence.

J Pharmacol Exp Ther

June 2018

Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics (M.H., E.L.d.R., C.Z., L.W., H.L., R.M.W.), and Division of Medical Oncology, Department of Oncology (J.N.I.), Mayo Clinic, Rochester, Minnesota; Division of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, Massachusetts (P.E.G.); Canadian Cancer Trials Group, Kingston, Ontario, Canada (L.E.S.); and RIKEN Center for Integrative Medical Science, Yokohama, Japan (M.K.)

T-cell leukemia 1A () single-nucleotide polymorphisms (SNPs) have been associated with aromatase inhibitor-induced musculoskeletal adverse events. We previously demonstrated that TCL1A is inducible by estradiol (E) and plays a critical role in the regulation of cytokines, chemokines, and Toll-like receptors in a SNP genotype and estrogen-dependent fashion. Furthermore, SNP-dependent expression phenotypes can be "reversed" by exposure to selective estrogen receptor modulators such as 4-hydroxytamoxifen (4OH-TAM).

View Article and Find Full Text PDF

Single-Nucleotide Polymorphisms and Estrogen-Mediated Toll-Like Receptor-MYD88-Dependent Nuclear Factor-B Activation: Single-Nucleotide Polymorphism- and Selective Estrogen Receptor Modulator-Dependent Modification of Inflammation and Immune Response.

Mol Pharmacol

August 2017

Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics (M.-F.H., L.W., R.M.W.), Division of Medical Oncology, Department of Oncology (J.N.I.), and Division of Biomedical Statistics and Informatics, Department of Health Sciences Research (K.R.K.), Mayo Clinic, Rochester, Minnesota; Department of Emergency Medicine, Vanderbilt Medical Center, Nashville, Tennessee (T.B.); Division of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, Massachusetts (P.E.G.); NCIC Clinical Trials Group, Kingston, Ontario Canada (L.E.S.); and RIKEN Center for Integrative Medical Science, Tsurumi-ku, Yokohama, Japan (T.M., M.K.)

In a previous genome-wide association study (GWAS) for musculoskeletal adverse events during aromatase inhibitor therapy for breast cancer, we reported that single nucleotide polymorphisms (SNPs) near the gene were associated with this adverse drug reaction. Functional genomic studies showed that TCL1A expression was induced by estradiol, but only in cells with the variant sequence for the top GWAS SNP (rs11849538), a SNP that created a functional estrogen response element. In addition, genotype influenced the downstream expression of a series of cytokines and chemokines and had a striking effect on nuclear factor B (NF-B) transcriptional activity.

View Article and Find Full Text PDF

Estrogen, SNP-Dependent Chemokine Expression and Selective Estrogen Receptor Modulator Regulation.

Mol Endocrinol

March 2016

Division of Clinical Pharmacology (M.-F.H., M.L., L.W., R.M.W.), Department of Molecular Pharmacology and Experimental Therapeutics, Division of Rheumatology (M.-F.H., T.B.), Department of Medicine, Division of Biomedical Statistics and Informatics (K.R.K.), Department of Health Sciences Research, and Division of Medical Oncology (M.P.G., J.N.I.), Department of Oncology, Mayo Clinic, Rochester, Minnesota 55905; Division of Hematology/Oncology (P.E.G.), Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard University, Boston, Massachusetts 02114; National Cancer Institute of Canada Clinical Trials Group (L.E.S.), Kingston, Ontario, Canada K7L 3N6; and RIKEN Center for Integrative Medical Science (M.K.), Yokohama 230-0045, Japan.

We previously reported, on the basis of a genome-wide association study for aromatase inhibitor-induced musculoskeletal symptoms, that single-nucleotide polymorphisms (SNPs) near the T-cell leukemia/lymphoma 1A (TCL1A) gene were associated with aromatase inhibitor-induced musculoskeletal pain and with estradiol (E2)-induced TCL1A expression. Furthermore, variation in TCL1A expression influenced the downstream expression of proinflammatory cytokines and cytokine receptors. Specifically, the top hit genome-wide association study SNP, rs11849538, created a functional estrogen response element (ERE) that displayed estrogen receptor (ER) binding and increased E2 induction of TCL1A expression only for the variant SNP genotype.

View Article and Find Full Text PDF

Aromatase inhibitor-associated bone fractures: a case-cohort GWAS and functional genomics.

Mol Endocrinol

October 2014

Division of Clinical Pharmacology (M.L., L.W., R.M.W.), Department of Molecular Pharmacology and Experimental Therapeutics; Departments of Oncology (J.N.I.) and Health Sciences Research (A.B., G.D.J., E.E.C., D.J.S.); and Division of Endocrinology (S.K.), Mayo Clinic, Rochester, Minnesota 55905; Massachusetts General Hospital (P.E.G.), Harvard University, Boston, Massachusetts 02114; Rikagaku Kenkyūsho Center for Integrative Medical Science (M.K., Y.F.), Yokohama, Japan 230-0045; School of Medicine (Y.N.), Chicago University, Chicago, Illinois 60637; National Cancer Institute of Canada Clinical Trials Group (J.-A.W.C., L.E.S.), Kingston, Ontario, Canada K7L 3N6; and Division of Oncology (M.J.E.), Department of Medicine, Washington University School of Medicine, St Louis, Missouri 63110.

Bone fractures are a major consequence of osteoporosis. There is a direct relationship between serum estrogen concentrations and osteoporosis risk. Aromatase inhibitors (AIs) greatly decrease serum estrogen levels in postmenopausal women, and increased incidence of fractures is a side effect of AI therapy.

View Article and Find Full Text PDF

When a student is away from school for an extended time due to illness, he/she is provided with a tutor or access to in-hospital classrooms to keep up with his/her studies. This isolates the child from normal classroom experiences. A remote-control videoconferencing system (VCS), P.

View Article and Find Full Text PDF